Mdm2-SNP309 polymorphism in prostate cancer
Author Information
Author(s): Stoehr R, Hitzenbichler F, Kneitz B, Hammerschmied C G, Burger M, Tannapfel A, Hartmann A
Primary Institution: Institute of Pathology, University Hospital Erlangen
Hypothesis
Does the Mdm2 SNP309 polymorphism influence prostate cancer risk or histopathological characteristics?
Conclusion
The study found no correlation between the Mdm2 SNP309 polymorphism and increased prostate cancer risk or prognosis.
Supporting Evidence
- The genotype distribution in cases and controls did not differ significantly.
- Age at disease onset was not modified by the SNP.
- There was no significant correlation of genotypes and disease recurrence or Gleason score.
Takeaway
The study looked at a gene variant to see if it affects prostate cancer risk, but it found that it doesn't.
Methodology
A case-control study comparing 145 prostate cancer patients with 124 male controls using RFLP analysis.
Limitations
The study only included male subjects and may not be generalizable to other populations.
Participant Demographics
145 male prostate cancer patients and 124 male controls without malignancy.
Statistical Information
P-Value
0.299
Confidence Interval
95% CI: 0.413–1.120
Statistical Significance
p=0.299
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website